Be the first person to write a business review for Cellectis SA

Celsis International plc company was founded in 1992. Celsis International is all about playing it safe. Through the company's Product Group, it makes rapid diagnostic and monitoring systems used to detect and measure microbial contamination in consumer products and food. Its RapidScreen assays are used by makers of personal care goods, cosmetics, OTC drugs, and a variety of beverages. CellScan Innovate is used by dairy producers. The division, which accounts for little more than half of Celsis International's sales, counts among its customers Dow Corning and Gillette. Celsis Laboratory Group performs quality testing for the cosmetics, drug, and chemicals industries.

Centocor Ortho Biotech has ways of making your immune system behave itself. The Johnson & Johnson subsidiary makes blockbuster biotech drug Remicade, a monoclonal antibody used to treat a number of autoimmune conditions, or diseases in which the body's immune system attacks its own tissues. It is approved in the US and Europe for several indications, including Crohn's disease, ulcerative colitis, psoriasis, rheumatoid arthritis, and ankylosing spondylitis (a type of arthritis of the spine). The company also makes oncology drugs Doxil and Leustatin, and immunosuppressant Orthoclone for organ transplantation.

Ceragenix Pharmaceuticals was founded in 2002 is based in Denver, Colorado. Ceragenix Pharmaceuticals, Inc. operates as a medical device company focusing on infectious diseases and dermatology in the United States. The company has two base technology platforms, which include Ceragenins for the treatment of infectious disease; and Barrier Repair for the treatment of dermatological disorders, including atopic dermatitis, neonatal skin disorders, and others. Its Ceragenin compounds are active against a range of gram positive and negative bacteria. The company uses its Ceragenin technology to formulate Cerashield antimicrobial coatings for medical devices. Its Barrier Repair technology is the platform for the development of two prescription topical creams, including EpiCeram, a prescription product for the treatment of dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatoses, including eczema, irritant contact dermatitis, and radiation dermatitis; and NeoCeram, a pediatric barrier repair cream intended to create a skin barrier in premature infants and neonates.

Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.

Cerep offers tools and knowledge to help those companies discover and develop new drugs without having to start from scratch. It also developed a library of compounds that includes promising substances and drug candidates developed with Bristol-Myers Squibb and Sanofi-Aventis. Customers use Cerep's expertise in compound profiling, computational chemistry, in vitro and in vivo pharmacology, and pharmacoinformatics to cut to the chase and develop successful drug candidates.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.